Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie cuts 2026 EPS guidance to $13.91-$14.11 after $291 million Q2 IPR&D charge

Negative Impact 4 of 5 guidance Written later

AbbVie said its second-quarter 2026 results will include $291 million in pre-tax acquired IPR&D and milestones expense, which lowers both GAAP and adjusted diluted earnings per share by $0.17. The company cut its full-year 2026 adjusted EPS guidance to $13.91-$14.11 from $14.08-$14.28, so shareholders face lower expected earnings for the year. Second-quarter results have not been finalized and may differ from these preliminary figures.

Key points

  • Q2 2026 acquired IPR&D and milestones expense of $291 million pre-tax, reducing GAAP and adjusted diluted EPS by $0.17
  • Q2 2026 adjusted diluted EPS guidance now $3.57-$3.61, down from $3.74-$3.78
  • Full-year 2026 adjusted diluted EPS guidance now $13.91-$14.11, down from the $14.08-$14.28 range announced April 29, 2026
  • Quarter ended June 30, 2026 results are not final and could differ from the preliminary estimates

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECJul 6, 2026, 4:12 PM ET
Accession number0001551152-26-000021

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 06, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.